Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer.
about
Adjuvant, neoadjuvant, and experimental regimens in overcoming pancreatic ductal adenocarcinomaEstablishment and characterization of 6 novel patient-derived primary pancreatic ductal adenocarcinoma cell lines from Korean pancreatic cancer patients.Effect of FOLFIRINOX as second-line chemotherapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy failure.Retrospective analysis of high intensity focused ultrasound combined with S-1 in the treatment of metastatic pancreatic cancer after failure of gemcitabineA randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer.Therapeutic efficacy and safety of S-1-based combination therapy compare with S-1 monotherapy following gemcitabine failure in pancreatic cancer: a meta-analysisSafety and efficacy of stereotactic body radiation therapy combined with S-1 simultaneously followed by sequential S-1 as an initial treatment for locally advanced pancreatic cancer (SILAPANC) trial: study design and rationale of a phase II clinicalRecent advances for the treatment of pancreatic and biliary tract cancer after first-line treatment failure.Second-line treatment in patients with pancreatic ductal adenocarcinoma: A meta-analysis.S-1 monotherapy versus S-1 combination therapy in gemcitabine-refractory advanced pancreatic cancer: A meta-analysis (PRISMA) of randomized control trials.Nanoliposomal irinotecan plus fluorouracil and folinic acid: a new treatment option in metastatic pancreatic cancer.Intravenous and intraperitoneal paclitaxel with S-1 for treatment of refractory pancreatic cancer with malignant ascites.Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer.Chemotherapy in Pancreatic Cancer: A Systematic ReviewCurrent status and dilemma of second-line treatment in advanced pancreatic cancer: is there a silver lining?
P2860
Q28074614-1C9BC108-7D8D-4B20-8DCE-05DD78AD90CBQ33582635-60776FA3-0D4E-4BA1-BA9E-C6542C7F3918Q33672571-E670FCCA-C926-4A1D-AB8F-CD13232BC8DCQ36595053-9EB45C2C-2469-4D49-A760-F188521D2064Q36627201-86733982-9BAF-4AD2-847C-A424744BDD23Q37408595-AC2B7C45-7BAC-46A6-A2B4-249E7F4BC37EQ37517051-B62DEA15-A4A9-45CE-B802-444486D8A568Q38577917-B2F67FB9-448A-4005-9232-F0CA07197421Q38620187-24804EFE-0777-47B4-9638-891A1B3F15C4Q38660283-D775925E-1E26-4F98-A566-C370CA2654E9Q38797818-70011F57-7F72-4C25-B841-4E17A2168484Q40638288-CDDDF7A2-C3A2-4028-BA27-2FB640FAD885Q55338108-3932A47C-EF17-49E0-8CCF-791C14F9ADC3Q57824846-FCFDD114-967F-43DD-8A1B-74975E20A09CQ58799265-2964D095-1094-4C7E-92AD-CFA26AC25217
P2860
Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer.
description
2015 nî lūn-bûn
@nan
2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Randomised phase II trial of S ...... -refractory pancreatic cancer.
@ast
Randomised phase II trial of S ...... -refractory pancreatic cancer.
@en
type
label
Randomised phase II trial of S ...... -refractory pancreatic cancer.
@ast
Randomised phase II trial of S ...... -refractory pancreatic cancer.
@en
prefLabel
Randomised phase II trial of S ...... -refractory pancreatic cancer.
@ast
Randomised phase II trial of S ...... -refractory pancreatic cancer.
@en
P2093
P2860
P356
P1476
Randomised phase II trial of S ...... e-refractory pancreatic cancer
@en
P2093
A Fukutomi
A Funakoshi
G Wakabayashi
G Watanabe
H Yanagimoto
P2860
P2888
P304
P356
10.1038/BJC.2015.103
P407
P50
P577
2015-04-16T00:00:00Z
P5875
P6179
1006465045